STOCK TITAN

XOMA to Present at Upcoming Investor Conferences in March

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
XOMA Corporation announces participation in upcoming investor conferences in March 2024, with key executives presenting at TD Cowen Health Care Conference and Leerink Partners Global Biopharma Conference.
Positive
  • None.
Negative
  • None.

EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences:

  • The 44th Annual TD Cowen Health Care Conference taking place March 4-6, 2024, in Boston, MA.  Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat on Wednesday, March 6, 2024, at 10:30 AM ET.  The presentation can be accessed at https://bit.ly/4939Ico.
  • The Leerink Partners 2024 Global Biopharma Conference, which is being held March 11-13, 2024, in Miami, FL.  Mr. Hughes will present the corporate overview on Monday, March 11, 2024, at 10:40 AM ET.  The presentation can be accessed at https://bit.ly/3SxDK0E.

XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event.

About XOMA Corporation
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com.

  
XOMA Investor ContactXOMA Media Contact
Juliane SnowdenKathy Vincent
XOMA CorporationKV Consulting & Management
+1 646-438-9754+1 310-403-8951
juliane.snowden@xoma.comkathy@kathyvincent.com
  


XOMA Corporation executives will participate in the TD Cowen Health Care Conference on March 4-6, 2024.

Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will represent XOMA Corporation at the investor conferences.

Investors can access the presentations by XOMA Corporation executives at the company's website www.xoma.com or through the provided links.

The presentations by XOMA Corporation executives will be available for replay and archived on the website for 90 days after the events.
XOMA Corp

NASDAQ:XOMA

XOMA Rankings

XOMA Latest News

XOMA Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Berkeley

About XOMA

xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.